|
Dr Reddy’s Lab Q3 PAT drops 14% YoY to Rs 1,210 cr> |
|
Dr Reddy's Laboratories consolidated net profit declines 14.42% in the December 2025 quarter> |
|
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03> |
|
Dr Reddys Laboratories to announce Quarterly Result> |
|
Dr Reddys Laboratories allots 9,165 equity shares under ESOS> |
|
Dr Reddy’s Lab arm inks pact with Immutep SAS for novel cancer immunotherapy> |
|
Dr Reddys Laboratories Ltd up for five straight sessions> |
|
Dr Reddys Lab gains after securing EC nod for AVT03> |
|
Dr. Reddy's receives EC marketing authorization for AVT03 (denosumab)> |
|
Dr Reddys Laboratories Ltd up for fifth session> |